Agenus | AGEN - Ordinary Share Capital


Agenus reported $38.52M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 608K Jun/2026
Agenus USD 38.52M 3.2M Mar/2026
Amgen USD 541M 0 Sep/2026
AstraZeneca USD 1.55B 28K Sep/2026
Bristol-Myers Squibb USD 2.04B 7M Jun/2026
Celldex Therapeutics USD 78.5M 11.93M Jun/2026
CSL USD 482.13M 93.87M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 2.02B 2.05B Sep/2026
Glaxosmithkline GBP 2.02B 2.03B Sep/2026
Incyte USD 200.98M 1.03M Jun/2026
Intrexon USD 0 0 Jun/2024
J&J USD 2.41B 1.64M Jun/2026
Jiangsu Hengrui CNY 6.64B 0 Sep/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
MacroGenics USD 63.65M 86K Jun/2026
Merck EUR 434.78M 0 Jun/2026
Merck USD 2.47B 1.05M Jun/2026
Northwest Biotherapeutics USD 1.61B 88.6M Mar/2026
Novartis USD 1.89B 12.09M Sep/2026
Novavax USD 162.58M 106K Dec/2025
Pfizer USD 5.7B 0 Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Veracyte USD 80.39M 598K Sep/2026